Skip to content

Effectiveness of electric moxibustion for chronic upper-limb lymphedema in patients with breast cancer: A pilot feasibility study

Effectiveness of electric moxibustion for chronic upper-limb lymphedema in patients with breast cancer: A pilot feasibility study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003423
Enrollment
10
Registered
2019-01-15
Start date
2018-06-14
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : - experimental group: electric moxibustion therapy for 8weeks (total 16 sessions, 30minutes/session) - treatment site: 6 acupoints in upper limbs (both LI14, LI11, TE5)

Sponsors

Dunsan Korean Medicine Hospital of Daejeon University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) Woman over 19 years old who have diagnosed with breast cancer (2) Subjects who completed primary cancer treatment at least 6 months ago (Hormone therapy can be used in combination) (3) Subjects with lymphedema in the upper limb of the treated area by breast cancer surgery or radiotherapy (4) Subjects with lymphedema for at least 6 months and who still have lymphedema (5) Subjects who has more than 10 mm differences of arm circumference between both upper limbs. (6) Subjects with Eastern Cooperative Oncology Group (ECOG) performance status below 2 points (7) Subjects who signed a written agreement

Exclusion criteria

Exclusion criteria: (1) Subjects who already had lymphedema before breast cancer treatment (2) Recurred breast cancer, or metastasis of cancer (3) Subjects with other diseases that can affect edema, such as severe heart failure, kidney failure, cirrhosis (4) Abnormal liver function test, kidney function test, hepatic or renal function tests (AST, ALT more than twice the upper limit of the normal range, or creatinine is 2.0 mg/dL or more) (5) Lymphedema accompanied deformed bones, or vascular malformations (6) HbA1c more than 10% (7) Platelet count below 60,000/µL, Hemoglobin below 8 g/dL, or Absolute Neutrophil Count(ANC) below 1,000 (8) White blood cell(WBC) above 10,000/µL (9) Subjects with life expectancy less than 6 months (10) Subjects plainning to undergo surgery, chemotherapy, and radiation therapy during the trial (11) Subjects who have been actively treated for improvement of lymphatic edema within the last 4 weeks (Compression stockings, compression bandages etc. are allowed) (12) Subjects who have participated in other clinical trials within the last 4 weeks (13) Subjects who had experienced hypersensitivity reactions or serious adverse reactions after moxibustion treatment

Design outcomes

Primary

MeasureTime frame
Circumference of upper limbs

Secondary

MeasureTime frame
Shoulder ROM;Quality of Life;Edema index of upper limbs

Countries

Korea, Republic of

Contacts

Public ContactHwa-Seung Yoo

Dunsan Korean Medicine Hospital of Daejeon University

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026